Cor Vasa 2014, 56(5):582-585 | DOI: 10.33678/cor.2014.052
Dabigatran-etaxilát: Nově schválená indikace léčby a prevence rekurence hluboké žilní trombózy a plicní embolie
Published: October 1, 2014 Show citation
References
- http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm
- S.J. Connolly, M.D. Ezekowitz, S. Yusuf, et al., Dabigatran versus warfarin in patients with atrial fibrillation, New England Journal of Medicine 361 (2009) 1139-1151.
Go to original source...
Go to PubMed...
- S.J. Connolly, M.D. Ezekowitz, S. Yusuf, et al., Newly identified events in the RE-LY trial, New England Journal of Medicine 363 (2010) 1875-1876.
Go to original source...
Go to PubMed...
- Pradaxa®: EU SPC, 2014.
- S. Schulman, A.K. Kakkar, S.Z. Goldhaber, et al., Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation 129 (2014) 764-772.
Go to original source...
Go to PubMed...
- S. Schulman, C. Kearon, A.K. Kakkar, et al., Extended use of dabigatran, warfarin, or placebo in venous thromboembolism, New England Journal of Medicine 368 (2013) 709-718.
Go to original source...
Go to PubMed...
- S. Schulman, et al., Abstract 1136. Presented at ASH 2013.